Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus
Phase 2
Suspended
- Conditions
- Gastric CancerEsophageal Neoplasms
- Registration Number
- NCT00048529
- Lead Sponsor
- Tularik
- Brief Summary
This is a clinical research study of T900607-sodium to determine if it is effective and safe in treating gastric cancer and adenocarcinoma of the esophagus. Patients will be treated on a weekly basis with an intravenous injection of the study drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- SUSPENDED
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
Pacific Oncology Associates
🇺🇸Los Gatos, California, United States
Scripps Health Center
🇺🇸San Diego, California, United States
Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
University of New Mexico Cancer Research and Treatment Center
🇺🇸Albuquerque, New Mexico, United States
Ireland Cancer Center
🇺🇸Cleveland, Ohio, United States
Pacific Oncology Associates🇺🇸Los Gatos, California, United States